Geoffrey Greene

List of Publications by Year
in descending order

55	11,249	126708	168136
papers	citations	33	53
		h-index	g-index

61	61	61	9581
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Selective pressure of endocrine therapy activates the integrated stress response through NFÎºB signaling in a subpopulation of ER positive breast cancer cells. Breast Cancer Research, 2022, 24, 19.	2.2	6
2	Endocrine Therapy-Resistant Breast Cancer Cells Are More Sensitive to Ceramide Kinase Inhibition and Elevated Ceramide Levels Than Therapy-Sensitive Breast Cancer Cells. Cancers, 2022, 14, 2380.	1.7	4
3	Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in ESR1 mutant breast cancer cells. ELife, 2022, 11, .	2.8	11
4	Labeling of a Mutant Estrogen Receptor with an Affimer in a Breast Cancer Cell Line. Biophysical Journal, 2022, , .	0.2	1
5	Rapid Induction of the Unfolded Protein Response and Apoptosis by Estrogen Mimic TTC-352 for the Treatment of Endocrine-Resistant Breast Cancer. Molecular Cancer Therapeutics, 2021, 20, 11-25.	1.9	11
6	Facilitating Drug Discovery in Breast Cancer by Virtually Screening Patients Using In Vitro Drug Response Modeling. Cancers, 2021, 13, 885.	1.7	6
7	Reinvestigating the acyl cyclization to the precursor of diptoindonesin G. Tetrahedron Letters, 2021, 69, 152980.	0.7	0
8	Defining the Energetic Basis for a Conformational Switch Mediating Ligand-Independent Activation of Mutant Estrogen Receptors in Breast Cancer. Molecular Cancer Research, 2021, 19, 1559-1570.	1.5	6
9	Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer. Breast Cancer Research, 2021, 23, 54.	2.2	38
10	Neutrophil elastase selectively kills cancer cells and attenuates tumorigenesis. Cell, 2021, 184, 3163-3177.e21.	13.5	119
11	A small-molecule activator of the unfolded protein response eradicates human breast tumors in mice. Science Translational Medicine, 2021, 13, .	5.8	20
12	The Structure-Function Relationship of Angular Estrogens and Estrogen Receptor Alpha to Initiate Estrogen-Induced Apoptosis in Breast Cancer Cells. Molecular Pharmacology, 2020, 98, 24-37.	1.0	19
13	The NF-Î°B Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptorâ€“Positive Breast Cancers. Molecular Cancer Research, 2020, 18, 1018-1027.	1.5	31
14	Versatile Peptide Macrocyclization with Dielsâ€“Alder Cycloadditions. Journal of the American Chemical Society, 2019, 141, 16374-16381.	6.6	32
15	Next-Generation ERÎ± Inhibitors for Endocrine-Resistant ER+ Breast Cancer. Endocrinology, 2019, 160, 759-769.	1.4	42
16	Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance. Nature Reviews Cancer, 2018, 18, 377-388.	12.8	148
17	Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer. Clinical Cancer Research, 2018, 24, 3433-3446.	3.2	49
18	A â€œcross-stitchedâ€•peptide with improved helicity and proteolytic stability. Organic and Biomolecular Chemistry, 2018, 16, 3702-3706.	1.5	26

#	Article	IF	Citations
19	Antagonists for Constitutively Active Mutant Estrogen Receptors: Insights into the Roles of Antiestrogen-Core and Side-Chain. ACS Chemical Biology, 2018, 13, 3374-3384.	1.6	8
20	Endoxifen, 4-Hydroxytamoxifen and an Estrogenic Derivative Modulate Estrogen Receptor Complex Mediated Apoptosis in Breast Cancer. Molecular Pharmacology, 2018, 94, 812-822.	1.0	24
21	Specific stereochemistry of OP-1074 disrupts estrogen receptor alpha helix 12 and confers pure antiestrogenic activity. Nature Communications, 2018, 9, 2368.	5.8	42
22	Progesterone receptor isoforms, agonists and antagonists differentially reprogram estrogen signaling. Oncotarget, 2018, 9, 4282-4300.	0.8	49
23	The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells. ELife, 2018, 7, .	2.8	72
24	Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists. Cancer Discovery, 2017, 7, 277-287.	7.7	286
25	Interferon-Stimulated Genes Are Transcriptionally Repressed by PR in Breast Cancer. Molecular Cancer Research, 2017, 15, 1331-1340.	1.5	29
26	Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation. ELife, 2016, 5, .	2.8	212
27	Stapled Peptides with Î³â€Methylated Hydrocarbon Chains for the Estrogen Receptor/Coactivator Interaction. Angewandte Chemie - International Edition, 2016, 55, 4252-4255.	7.2	73
28	Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer. Science Advances, 2016, 2, e1501924.	4.7	100
29	14q32-encoded microRNAs mediate an oligometastatic phenotype. Oncotarget, 2015, 6, 3540-3552.	0.8	103
30	ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nature Genetics, 2013, 45, 1439-1445.	9.4	960
31	MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion. Breast Cancer Research and Treatment, 2013, 137, 373-382.	1.1	90
32	MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nature Communications, 2013, 4, 1393.	5.8	209
33	Overcoming mutation-based resistance to antiandrogens with rational drug design. ELife, 2013, 2, e00499.	2.8	334
34	Mapping ERÎ² Genomic Binding Sites Reveals Unique Genomic Features and Identifies EBF1 as an ERÎ² Interactor. PLoS ONE, 2013, 8, e71355.	1.1	11
35	RAC3 is a pro-migratory co-activator of ERÎ±. Oncogene, 2011, 30, 1984-1994.	2.6	28
36	Removal of lactate dehydrogenase-elevating virus from human-in-mouse breast tumor xenografts by cell-sorting. Journal of Virological Methods, 2011, 173, 266-270.	1.0	22

#	Article	IF	Citations
37	Green tea catechins inhibit angiogenesis through suppression of STAT3 activation. Breast Cancer Research and Treatment, 2009, 117, 505-515.	1.1	56
38	Inhibition of mammary tumorigenesis in the C3(1)/SV40 mouse model by green tea. Breast Cancer Research and Treatment, 2008, 107, 359-369.	1.1	42
39	NFÎºB selectivity of estrogen receptor ligands revealed by comparative crystallographic analyses. Nature Chemical Biology, 2008, 4, 241-247.	3.9	149
40	Molecular characterization of a B-ring unsaturated estrogen: Implications for conjugated equine estrogen components of Premarin. Steroids, 2008, 73, 59-68.	0.8	32
41	Identification of Ligands with Bicyclic Scaffolds Provides Insights into Mechanisms of Estrogen Receptor Subtype Selectivity*. Journal of Biological Chemistry, 2006, 281, 17909-17919.	1.6	51
42	Recruitment of Histone Deacetylase 4 to the N-Terminal Region of Estrogen Receptor Î±. Molecular Endocrinology, 2005, 19, 2930-2942.	3.7	37
43	Structural Basis for an Unexpected Mode of SERM-Mediated ER Antagonism. Molecular Cell, 2005, 18, 413-424.	4.5	225
44	A Structural Explanation for ERÎ±/ERÎ² SERM Discrimination. , 2004, , 33-45.		2
45	Allosteric Control of Ligand Selectivity between Estrogen Receptors Î± and Î². Molecular Cell, 2004, 13, 317-327.	4.5	100
46	Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nature Structural Biology, 2002, 9, 359-64.	9.7	188
47	Estrogen Inhibits Vascular Smooth Muscle Cellâ€"Dependent Adventitial Fibroblast Migration In Vitro. Circulation, 1999, 100, 1639-1645.	1.6	55
48	The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen. Cell, 1998, 95, 927-937.	13.5	2,441
49	Molecular basis of agonism and antagonism in the oestrogen receptor. Nature, 1997, 389, 753-758.	13.7	3,139
50	Molecular characterization by mass spectrometry of the human estrogen receptor ligand-binding domain expressed in Escherichia coli.. Molecular Endocrinology, 1995, 9, 647-658.	3.7	26
51	Analysis of the Structural Core of the Human Estrogen Receptor Ligand Binding Domain by Selective Proteolysis/Mass Spectrometric Analysis. Biochemistry, 1995, 34, 12605-12615.	1.2	72
52	Identification of cysteine 530 as the covalent attachment site of an affinity-labeling estrogen (ketononestrol aziridine) and antiestrogen (tamoxifen aziridine) in the human estrogen receptor. Journal of Biological Chemistry, 1989, 264, 17476-85.	1.6	65
53	Estrogen and Progestin Receptors and Aromatase Activity in Rhesus Monkey Prostate*. Endocrinology, 1988, 123, 2312-2322.	1.4	62
54	Sequence and expression of human estrogen receptor complementary DNA. Science, 1986, 231, 1150-1154.	6.0	1,223

#	Article	IF	Citations
55	Characterization of the Subunit Nature of Nuclear Estrogen Receptors by Chemical Cross-Linking and Dense Amino Acid Labeling*. Endocrinology, 1985, 117, 515-522.	1.4	57